Evolution of portal-systemic collateral vasopressin response in endotoxemic portal hypertensive rats

Shock

Volumn 32, Issue 5, 2009, Pages 503-508

  Huang, Hui Chun ^a,b   Wang, Sun Sang ^b,c   Chang, Ching Chih ^a,b   Lee, Fa Yauh ^a,b   Lin, Han Chieh ^a,b   Hou, Ming Chih ^a,b   Teng, Tzu Hua ^a   Chen, Yi Chou ^a   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MUNICIPAL GAN DAU HOSPITAL   (Taiwan)

Author keywords

Endothelin 1; LPS; NO; Portal vein ligation; Portal systemic shunting

Indexed keywords

ARGIPRESSIN; ENDOTHELIN 1; NITRIC OXIDE;

ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DISEASE MODEL; ENDOTOXEMIA; HEMODYNAMICS; NONHUMAN; PERFUSION PRESSURE; PORTAL HYPERTENSION; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENORENAL SHUNT; TACHYCARDIA; VEIN LIGATION;

ANIMALS; ARGININE VASOPRESSIN; ENDOTHELIN-1; ENDOTOXEMIA; HEMODYNAMICS; HYPERTENSION, PORTAL; LIPOPOLYSACCHARIDES; MALE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASOCONSTRICTOR AGENTS;

EID: 70350213116     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181a1bf86     Document Type: Article

References (39)

1. Sikuler E, Kravetz D, Groszmann RJ: Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 248: G618YG625, 1985.
2. Harry D, Anand R, Holt S, Davies S, Marley R, Fernando B, Goodier D, Moore K: Increased sensitivity to endotoxemia in the bile duct-ligated cirrhotic Rat. Hepatology 30:1198-1205, 1999.
3. Sorell WT, Quigley EM, Jin G, Johnson TJ, Rikkers LF: Bacterial trans-location in the portal-hypertensive rat: studies in basal conditions and on exposure to hemorrhagic shock. Gastroenterology 104:1722-1726, 1993.
4. Goulis J, Patch D, Burroughs AK: Bacterial infection in the pathogenesis of variceal bleeding. Lancet 353:139-142, 1999.
5. Hou MC, Chen WC, Lin HC, Lee FY, Chang FY, Lee SD: A new Bsandwich[ method of combined endoscopic variceal ligation and sclerotherapy versus ligation alone in the treatment of esophageal variceal bleeding: a randomized trial. Gastrointest Endosc 53:572-578, 2001.
6. Hou MC, Lin HC, Liu TT, Kuo BI, Lee FY, Chang FY, Lee SD: Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 39:746-753, 2004.
7. Chu CJ, Lee FY, Wang SS, Lu RH, Tsai YT, Lin HC, Hou MC, Chan CC, Lee SD: Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-alpha and nitric oxide. Clin Sci 93:219-225, 1997.
8. Huang HC, Chu CJ, Lee FY, Chang FY, Wang SS, Lin HC, Hou MC, Chan CC, Wu SL, Chen CT, et al.: Chronic inhibition of nitric oxide ameliorates splanchnic hyposensitivity to glypressin in a hemorrhage-transfused rat model of portal hypertension. Scand J Gastroenterol 35:1308-1313, 2000.
9. Nakamura T, Kasai K, Sekiguchi Y, Banba N, Takahashi K, Emoto T, Hattori Y, Shimoda S: Elevation of plasma endothelin concentrations during endotoxin shock in dogs. Eur J Pharmacol 205:277-282, 1991.
10. Weitzberg E, Lundberg JM, Rudehill A: Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock 33:222-227, 1991.
11. Chan CC, Wang SS, Lee FY, Chang FY, Lin HC, Chu CJ, Chen CT, Huang HC, Lee SD: Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 33:816-820, 2001.
12. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA 3rd: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487-493, 2001.
13. D'Amico G, Pagliaro L, Bosch J: The treatment of portal hypertension: a meta-analytic review. Hepatology 22:332-354, 1995.
14. Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Chu CJ, Tai CC, Lai IN, Lee SD: Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 30:630-635, 1999.
15. Chojkier M, Groszmann RJ: Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres. Am J Physiol 240:G371YG375, 1981.
16. Mosca P, Lee FY, Kaumann AJ, Groszmann RJ: Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of the endothelium. Am J Physiol 263:G544YG550, 1992.
17. Lee FY, Colombato LA, Albillos A, Groszmann RJ: Administration of N5-nitro-L-arginine ameliorates portal-systemic shunting in poral-hypertensive rats. Gastroenterology 105:1464-1470, 1993.
18. Baker CH, Sutton ET, Zhou Z, Dietz JR: Microvascular vasopressin effects during endotoxin shock in the rat. Circ Shock 30:81-95, 1990.
19. Fatehi-Hassanabad Z, Parratt JR, Furman BL: Endotoxin-induced inhibition of mesenteric vasodilator responses to acetylcholine, bradykinin, and post-occlusion hyperemia in anesthetized rats. Shock 6:371-376, 1996.
20. Wylam ME, Samsel RW, Umans JG, Mitchell RW, Leff AR, Schumacker PT: Endotoxin in vivo impairs endothelium-dependent relaxation of canine arteries in vitro. Am Rev Respir Dis 142:1263-1267, 1990.
21. Bhagat K, Moss R, Collier J, Vallance P: Endothelial Bstunning[ following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res 32:822-829, 1996.
22. McIntyre RC Jr, Sheridan B, Agrafojo J, Fullerton DA: Endotoxin differentially impairs cyclic guanosine monophosphateYmediated relaxation in the pulmonary and systemic circulations. Crit Care Med 25:318-323, 1997.
23. Li T, Croce K, Winquist RJ: Regional differences in the effects of septic shock on vascular reactivity in the rabbit. J Pharmacol Exp Ther 261:959-963, 1992.
24. Zaedi S, Jesmin S, Maeda S, Shimojo N, Yamaguchi I, Goto K, Miyauchi T: Alterations in gene expressions encoding preproET-1 and NOS in pulmonary tissue in endotoxemic rats. Exp Biol Med 231:992-996, 2006. (Pubitemid 43845565)
25. Connelly L, Madhani M, Hobbs AJ: Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-inflammatory role for eNOS-derived no in vivo. J Biol Chem 280:10040-10046, 2005.
26. Scicluna JK, Mansart A, Ross JJ, Reilly CS, Brown NJ, Brookes ZL: Reduced vascular response to phenylephrine during exposure to lipopolysaccharide in vitro involves nitric oxide and endothelin 1. Shock 29:417-421, 2008.
27. Kolls J, Xie J, LeBlanc R, Malinski T, Nelson S, Summer W, Greenberg SS: Rapid induction of messenger RNA for nitric oxide synthase II in rat neutrophils in vivo by endotoxin and its suppression by prednisolone. Proc Soc Exp Biol Med 205:220-229, 1994.
28. Gardiner SM, Kemp PA, March JE, Bennett T: Influence of aminoguanidine and the endothelin antagonist, SB 209670, on the regional haemodynamic effects of endotoxaemia in conscious rats. Bri J Pharmacol 118:1822-1828, 1996.
29. Malyshev E, Tazi KA, Moreau R, Lebrec D: Discrepant effects of inducible nitric oxide synthase modulation on systemic and splanchnic endothelial nitric oxide synthase activity and expression in cirrhotic rats. J Gastroenterol Hepatol 22:2195-2201, 2007.
30. Schwartz D, Mendonca M, Schwartz I, Xia Y, Satriano J, Wilson CB, Blantz RC: Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest 100:439-448, 1997.
31. Kessler P, Bauersachs J, Busse R, Schini-Kerth VB: Inhibition of inducible nitric oxide synthase restores endothelium-dependent relaxations in proin-flammatory mediator-induced blood vessels. Arterioscler Thromb Vasc Biol 17:1746-1755, 1997.
32. Wright CE, Rees DD, Moncada S: Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 26:48-57, 1992.
33. Dschietzig T, Alexiou K, Laule M, Becker R, Schror K, Baumann G, Brunner F, Stangl K: Stimulation of pulmonary big endothelin-1 and endothelin-1 by antithrombin III: a rationale for combined application of antithrombin III and endothelin antagonists in sepsis-related acute respiratory distress syndrome? Crit Care Med 28:2445-2449, 2000.
34. Gardiner SM, Kemp PA, March JE, Bennett T: Temporal differences between the involvement of angiotensin II and endothelin in the cardiovascular responses to endotoxaemia in conscious rats. Bri J Pharmacol 119:1619-1627, 1996.
35. Thijs A, Thijs LG: Pathogenesis of renal failure in sepsis. Kidney Int Suppl 66:S34YS37, 1998.
36. Gandhi CR, Kuddus RH, Nemoto EM, Murase N: Endotoxin treatment causes an upregulation of the endothelin system in the liver: amelioration of increased portal resistance by endothelin receptor antagonism. J Gastroenterol Hepatol 16:61-69, 2001.
37. Kleber G, Braillon A, Gaudin C, Champigneulle B, Cailmail S, Lebrec D: Hemodynamic effects of endotoxin and platelet activating factor in cirrhotic rats. Gastroenterology 103:282-288, 1992.
38. Navaratnam RL, Morris SE, Traber DL, Flynn J, Woodson L, Linares H, Herndon DN: Endotoxin (LPS) increases mesenteric vascular resistance (MVR) and bacterial translocation (BT). J Trauma 30:1104-1113, 1990.
39. Kravetz D, Sikuler E, Groszmann RJ: Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 90:1232-1240, 1986.